// App-Quantinova.ai

EP1080 : BET INHIBITOR PELABRESIB DECREASES INFLAMMATORY CYTOKINES, IMPROVES BONE MARROW FIBROSIS AND FUNCTION, AND DEMONSTRATES CLINICAL RESPONSE IRRESPECTIVE OF MUTATION STATUS IN MYELOFIBROSIS PATIENTS

Researchers

Presenter

  • Patricia Keller

Principal Investigators

  • Jike Cui

  • Jennifer Mertz

  • Mohamed Salama

  • Oksana Zavidij

  • Srdan Verstovsek

  • Claire Harrison

  • John Mascarenhas

  • Moshe Talpaz

  • Ruben Mesa

  • Alessandro Vannucchi

  • Raajit Rampal

  • Stephen Oh

  • Gozde Colak

  • Katerina Luptakova

  • Jeffrey Humphrey

  • Jing Wang

  • Patrick Trojer

Medical Centers

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • AGIOS Pharmaceuticals Inc,Cambridge,United States

  • University of Michigan Cancer Center,Ann Arbor,United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,United States

  • Washington University in St. Louis, Siteman Cancer Center,St. Louis,United States

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

  • Mayo Clinic, Rochester, United States

Locations

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

  • CPI-0610

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • II

Study Id's

  • NCT02158858

  • NCT04603495

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved